1. Scrip
  2. >>Business

New Data Bolster Tecentriq Bid To Be First Adjuvant Immunotherapy In NSCLC

US FDA Decision Expected 1 December

 
• By Andrew McConaghie

Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.

Roche_Logo_Glass
Roche's Tecentriq is trailing Merck's Keytruda in advanced NSCLC, but could be first approved in an adjuvant setting.

Roche has presented new data to support the use of Tecentriq as an adjuvant treatment in early-stage non-small cell lung cancer (NSCLC), where it could soon be the first immunotherapy to gain approval.

Currently more than half of all people who are treated with surgery for early-stage (Stage II-IIIA) NSCLC see their cancer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip